StreetAlpha.app
Home › Stocks › SUPN

Supernus, Inc. (SUPN)

Healthcare
$29.04
▲ +0.73%
LAST CLOSE · NOV 17

Supernus is a Rockville, Maryland pharmaceutical company that sells prescription medicines to patients through healthcare providers. It last closed at $29.04 on Nov 17, up 0.73% on the day. The average 12-month price target from 3 analysts is $60.33 (+107.8% from the last close), with a high of $87.00 and a low of $47.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.9M, the largest $1.1M.

AI Auto Pilots
Is SUPN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.4B
+16.4% vs a year ago
Net income
$450.0M
+248.8% vs a year ago
EPS (diluted)
$3.57
+253.5% vs a year ago
Free cash flow
$31.0M
2.3% margin
Valuation
Market cap
$3.4B
118.0M shares
P/E
8.1
Price over 12 month EPS
Price to sales
2.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$305.0M
At Sep 30
Debt
$488.0M
At Sep 30
Shareholder equity
−$60.0M
Buybacks
$302.0M
Last 12 months
Employees1,000 (Jun 30, 2025)
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $791.0M$791.0MFY2021FY2022: $901.0M$901.0MFY2022FY2023: $1.1B$1.1BFY2023FY2024: $1.2B$1.2BFY2024FY2025: $1.2B$1.2BFY2025

From SUPN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on SUPN in the past 90 days
Average 12-month target
$60.33
▲ 107.8% upside

Based on 3 analysts who set a price target on SUPN in the past 90 days. The average target is $60.33, with a high of $87.00 and a low of $47.00, compared with the last close of $29.04.

Low $47.00Avg $60.33High $87.00
Blue marker: last close $29.04
Highest target$87.00
Average target$60.33
Lowest target$47.00
Latest rating changes
B of A SecuritiesInitiated
Nov 9Buy$47
Piper SandlerReinstated
Nov 4Buy$47
Cantor FitzgeraldTarget raised
Nov 4Buy$67 → $87
Cantor FitzgeraldMaintained
Jul 9Buy$67
DateFirmActionRatingPrice target
Nov 9B of A SecuritiesInitiatedBuy$47
Nov 4Piper SandlerReinstatedBuy$47
Nov 4Cantor FitzgeraldTarget raisedBuy$67 → $87
Jul 9Cantor FitzgeraldMaintainedBuy$67
Loading…

Whale Options Flow

90D

No whale options trades in SUPN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
2
Notional
$1.9M
Largest print
$1.1M
Loading…

SUPN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bearish
Strongly bearishNeutralStrongly bullish
  • ▼132 buying vs 178 selling
  • ▼Held by funds -2.8 pts
  • ▼Funds holding -39
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding294333−11.7%
In funds' top 1043+33.3%
Held by funds48.3%51.1%−2.8 pts
New / increased31 / 10144 / 119−19.0%
Reduced / sold out109 / 69112 / 35+21.1%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SUPN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SUPN is in one of them and how their past SUPN trades turned out.

SUPN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SUPN in an article yet. Here's the latest on the wider market.

SUPN Congress Trades

All congress trades →
Trades, 12 months
5
Buys
2
40%
Sells
3
60%
People
2
Last filed Sep 22
Who traded SUPN · since 2020
Latest 5 filings of 12
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Dec 11, 2025Filed Jan 12, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Oct 9, 2025Filed Nov 18, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KDec 11, 2025Jan 12, 202632 d
Gilbert CisnerosD · CASell (partial)$1K – $15KOct 9, 2025Nov 18, 202540 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Supernus

Supernus is a pharmaceutical company based in Rockville, Maryland. It develops and sells prescription medicines, which it markets through a sales force that calls on healthcare providers. Patients use these products, and government and private health programs help pay for them. The company sells in the United States and in other countries, and it also conducts research and development to bring new medicines to market.

Headquarters
Rockville, MD